Maximum Views Reached

You have reached the maximum number of Guideline views for today. By creating a free account, you can increase your number of complimentary daily views.

To view this Guideline, please log in to your account. If you do not have an account, you can create one for free by clicking the button below.

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers

Publication Date: December 14, 2022

Last Updated: March 27, 2023

Treatment

Recommendation 1.1

Programmed death-ligand 1 (PD-L1) immunohistochemistry testing should be performed in patients with recurrent HNSCC. (EB, B, H, S)

1048203

Overview

Title

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers

Treatment

Recommendation 1.1

Overview

Title

Authoring Organization